These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1516889)

  • 1. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion.
    Wurzburger MI; Prelevic GM; Sonksen PH; Balint-Peric LA
    Horm Metab Res; 1992 Jul; 24(7):329-32. PubMed ID: 1516889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes.
    Wurzburger MI; Prelevic GM; Sönksen PH; Balint-Peric LA; Wheeler M
    J Clin Endocrinol Metab; 1993 Jul; 77(1):267-72. PubMed ID: 8325951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
    Kirkegaard C; Nørgaard K; Snorgaard O; Bek T; Larsen M; Lund-Andersen H
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
    Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ
    Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
    Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
    Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy.
    Hyer SL; Sharp PS; Brooks RA; Burrin JM; Kohner EM
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):187-94. PubMed ID: 2916380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.
    Osei K; O'Dorisio TM; Malarkey WB; Cataland S
    J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of improved blood glucose on growth hormone and cortisol secretion in insulin-dependent diabetes mellitus.
    Würzburger MI; Prelevic GM; Sönksen PH; Peric LA; Till S; Morris RW
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):787-97. PubMed ID: 2200623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.
    Laursen T; Jørgensen JO; Orskov H; Møller J; Harris AG; Christiansen JS
    Acta Endocrinol (Copenh); 1993 Nov; 129(5):399-408. PubMed ID: 7506470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
    Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K
    Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
    Osei K; O'Dorisio TM; Malarkey WB; Craig EL; Cataland S
    Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four years' treatment of resistant acromegaly with octreotide.
    McKnight JA; McCance DR; Sheridan B; Atkinson AB
    Eur J Endocrinol; 1995 Apr; 132(4):429-32. PubMed ID: 7711880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus.
    Cheetham TD; Clayton KL; Taylor AM; Holly J; Matthews DR; Dunger DB
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):515-22. PubMed ID: 8187319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers.
    Aarsen RS; Bruining GJ; Grose WF; van Strik R; Lamberts SW; Harris AG
    Acta Endocrinol Suppl (Copenh); 1987; 286():45-53. PubMed ID: 2892337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus.
    Orskov L; Møller N; Bak JF; Pørksen N; Schmitz O
    Metabolism; 1996 Feb; 45(2):211-7. PubMed ID: 8596492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.